Drugs / [99mTc]Tc-Duramycin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05177640 | Jun → Dec 2021 | — | University Hospital, Antwerp | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [99mTc]Tc-Duramycin | “BACKGROUND: Imaging of cell death can provide an early indication of treatment response in cancer. [99mTc]Tc-Duramycin is a small-peptide SPECT tracer that recognizes both...” PMID 37646865 ↗ Aug 20231“First-in-human study of a novel cell death tracer [(99m)Tc]Tc-Duramycin: safety, biodistribution and radiation dosimetry in healthy volunteers.” PMID 37646865 ↗ Aug 2023 |
| Modality | Peptide | “[99mTc]Tc-Duramycin is a small-peptide SPECT tracer” PMID 37646865 ↗ Aug 2023 |
| Route | Intravenous | “were injected intravenously with [99mTc]Tc-Duramycin (dose: 6 MBq/kg; 473 ± 36 MBq)” PMID 37646865 ↗ Aug 2023 |